Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schoretsanitēs, Geōrgios [VerfasserIn]   i
 Baumann, Pierre [VerfasserIn]   i
 Conca, Andreas [VerfasserIn]   i
 Dietmaier, Otto [VerfasserIn]   i
 Giupponi, Giancarlo [VerfasserIn]   i
 Gründer, Gerhard [VerfasserIn]   i
 Hahn, Martina [VerfasserIn]   i
 Hart, Xenia Marlene [VerfasserIn]   i
 Havemann-Reinecke, Ursula [VerfasserIn]   i
 Hefner, Gudrun [VerfasserIn]   i
 Kuzin, Maxim [VerfasserIn]   i
 Mössner, Rainald [VerfasserIn]   i
 Piacentino, Daria [VerfasserIn]   i
 Steimer, Werner [VerfasserIn]   i
 Zernig, Gerald [VerfasserIn]   i
 Hiemke, Christoph [VerfasserIn]   i
Titel:Therapeutic drug monitoring of long-acting injectable antipsychotic drugs
Verf.angabe:Georgios Schoretsanitis, Pierre Baumann, Andreas Conca, Otto Dietmaier, Giancarlo Giupponi, Gerhard Gründer, Martina Hahn, Xenia Hart, Ursula Havemann-Reinecke, Gudrun Hefner, Maxim Kuzin, Rainald Mössner, Daria Piacentino, Werner Steimer, Gerald Zernig, Christoph Hiemke
E-Jahr:2021
Jahr:February 2021
Umfang:24 S.
Fussnoten:Gesehen am 01.07.2021
Titel Quelle:Enthalten in: Therapeutic drug monitoring
Ort Quelle:Philadelphia, Pa. : Lippincott Williams & Wilkins, 1979
Jahr Quelle:2021
Band/Heft Quelle:43(2021), 1, Seite 79-102
ISSN Quelle:1536-3694
Abstract:Background: The use of therapeutic drug monitoring (TDM) to guide treatment with long-acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of debate. The aim of this review was to provide a practical framework for the integration of TDM when switching from an oral formulation to the LAI counterpart, and in maintenance treatment. Methods: The authors critically reviewed 3 types of data: (1) positron emission tomography data evaluating dopamine (D2/D3) receptor occupancy related to antipsychotic concentrations in serum or plasma; D2/D3 receptors are embraced as target sites in the brain for antipsychotic efficacy and tolerability, (2) pharmacokinetic studies evaluating the switch from oral to LAI antipsychotics, and (3) pharmacokinetic data for LAI formulations. Based on these data, indications for TDM and therapeutic reference ranges were considered for LAI antipsychotics. Results: Antipsychotic concentrations in blood exhibited interindividual variability not only under oral but also under LAI formulations because these concentrations are affected by demographic characteristics such as age and sex, genetic peculiarities, and clinical variables, including comedications and comorbidities. Reported data combined with positron emission tomography evidence indicated a trend toward lower concentrations under LAI administration than under oral medications. However, the available evidence is insufficient to recommend LAI-specific therapeutic reference ranges. Conclusions: Although TDM evidence for newer LAI formulations is limited, this review suggests the use of TDM when switching an antipsychotic from oral to its LAI formulation. The application of TDM practice is more accurate for dose selection than the use of dose equivalents as it accounts more precisely for individual characteristics.
DOI:doi:10.1097/FTD.0000000000000830
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1097/FTD.0000000000000830
 Volltext: https://journals.lww.com/drug-monitoring/Abstract/2021/02000/Therapeutic_Drug_Monitoring_of_Long_Acting.9.aspx
 DOI: https://doi.org/10.1097/FTD.0000000000000830
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1761729039
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68754748   QR-Code
zum Seitenanfang